AI radiology company Aidoc revealed on Tuesday that the US Food and Drug Administration (FDA) has cleared the world's first AI solution for the treatment of cervical spine (C-spine) fractures.
This latest US FDA 510(k) clearance is reportedly the company's third in nine months and follows the recent US FDA clearance of the pulmonary embolism solution.
The company added that the AI-powered triage automatically prioritizes critical cases, ensuring that they are diagnosed by a radiologist in the most timely manner.
According to the company, the recent studies show that 54% of radiologists feel "burnt out" due to long work hours and on-the-job stress. AI-driven workflow triage is especially beneficial for empowering the radiologist by maintaining quality across the workflow, increasing confidence in treating critical patients on time, while making radiologists' work a lot more rewarding and less tedious.
In conjunction, the company's CEO Elad Walach will present its suite of AI-based workflow solutions at booth 513on an Ask Industry panel on the topic of 'AI in Practice – Where Are We Now?' at the SIIM 2019 annual meeting.
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Corcept announces receipt of FDA Complete Response letter for relacorilant in hypercortisolism
Axsome Therapeutics secures FDA priority review for AXS-05 in Alzheimer's disease agitation
Vanda's NEREUS approved by US FDA for prevention of motion sickness
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Citius Pharmaceuticals reports full-year financial results
Bioeq and Zydus partner for US commercialisation of Lucentis biosimilar NUFYMCO
Sanofi receives FDA complete response letter for tolebrutinib in progressive MS
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer